Salute e Benessere

Lecanemab winner in two categories at The Scrip Awards 2023

The award for Best New Drug recognizes excellence in pharmaceutical development and celebrates lecanemab as the first and only treatment approved in Japan and the United States shown to reduce the rate of disease progression and to slow cognitive and functional decline, which acts on the underlying pathology of Alzheimer's disease. The award for Best New Drug recognizes excellence in pharmaceutical development and celebrates lecanemab as the first and only treatment approved inJapanandthe...
PR Newswire
20/11/2023

Sobi to present new data at ASH 2023 Annual Meeting

Key data to be presented at ASH 2023 Key data to be presented at ASH 2023 Session: 322 Sunday, December 10, 2023, 12:00 PM - 1:30 PM Presentation Time: 12:15 PM Session: 322 Sunday, December 10, 2023, 12:00 PM - 1:30 PM Presentation Time: 12:30 PM Session: 904 Saturday, December 9, 2023, 5:30 PM - 7:30 PM Session: 322 Monday, December 11, 2023, 6:00 PM - 8:00 PM Session: 904 Saturday, December 9, 2023, 5:30 PM -...
PR Newswire
20/11/2023

Update on the merger approval process for the combination of Novozymes and Chr…

November 20, 2023 Please see attachment. Contact informationInvestor RelationsAnders Mohr Christensen +45 2515 2364dkamc@chr-hansen.comPress RelationsSanne Seyer-Hansen +45 6038 6207dksash@chr-hansen.comAttachment 2023_Update on the merger approval process for the combination of Novozymes and Chr. Hansen
Nasdaq GlobeNewswire
20/11/2023

Update on merger EC offered remedy proposal

Read the full announcement in PDF Attachment Update on merger EC offered remedy proposal
Nasdaq GlobeNewswire
20/11/2023

EPG and Raffles The Palm Dubai Debuts First of its Kind Luxury Branded…

"The Contemporary Collection" comprises a total of 30 freehold residences, ranging from 2 to 5 bedrooms, with sizes ranging from 2,500 square feet to an expansive 26,000 square feet with prices starting fromUS$ 5 Million (460 Million Russian Ruble). Inspired by Raffles' classic grandeur, the internationally renowned design group, Yodezeen, has meticulously crafted these residences to blend modern comfort with Art Deco opulence. This fusion of timeless classic and elegant contemporary…
PR Newswire
20/11/2023

Novartis showcases significant data updates from Kisqali®, iptacopan and…

Late-breaking final iDFS analysis from NATALEE investigating Kisqali ®(ribociclib) in broad population of patients with stage II and III HR+/HER2- early breast cancer, including those with node-negative diseaseNew 48-week efficacy and safety data from the Phase III APPLY-PNH trial of investigational oral monotherapy iptacopan in anti-C5-treated adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and persistent anemiaNearly 4 year follow-up efficacy and safety...
Nasdaq GlobeNewswire
20/11/2023

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and…

Allschwil, Switzerland, November 20, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba ®(isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”) in the Asia Pacific region and China exceeded the sales threshold triggering a further USD 1.25 million...
Nasdaq GlobeNewswire
20/11/2023

Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal…

Regulated information – Inside information Despite Prior Positive Data, THR-149 Did Not Demonstrate Improvement in Vision Oxurion's Board has Decided to Take Necessary Steps to File for Bankruptcy Leuven, BELGIUM, Boston, MA, US – November 20, 2023 – 7:00 am CET– Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company announced today that topline data in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) (KALAHARI trial) did not demonstrate...
Nasdaq GlobeNewswire
20/11/2023

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.Leuven, BELGIUM, Boston, MA, US – November 19, 2023 – 09.00 PM CET– In...
Nasdaq GlobeNewswire
19/11/2023

Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at…

Structural heart symposia on November 20 and 21 Structural heart symposia onNovember 20and 21 The company will be hosting two symposia onNovember 20and 21 that will allow interventional cardiologists to deepen their knowledge about structural heart interventions. The first, " Valve tricuspid Transcatheter: Cardiovalve keeps it in motion " will be dedicated to discussing the latest results and future plans for the Cardiovalve tricuspid valve replacement system. In the second, "...
PR Newswire
19/11/2023

Cellectis' Shareholders Meeting to be Held on December 22, 2023

thfloor, 75013 Paris, France. The notice of meeting as published today in the BALO (Bulletin des Annonces Legales Obligatoires), including the agenda, the text of the resolutions and the terms of participation, is online on the Cellectis website at the following address: https://www.cellectis.com/en/investors/general-meetings/About CellectisCellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies...
Nasdaq GlobeNewswire
17/11/2023

HIV Drugs Market to Reach $51.1 Billion, Globally, by 2032 at 4.5% CAGR: Allied…

Request Sample of the Report on HIV Drugs Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/1867 Request Sample of the Report on HIV Drugs Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/1867 Prime determinants of growth Increase in initiatives taken by various government associations to raise awareness about diagnosis and management of HIV in developing countries, rise in demand for HIV drugs, and rise in R&D regarding HIV...
PR Newswire
17/11/2023

Cleanroom Technology in Healthcare Market to reach $8.6 Billion, Globally, by…

Request Sample of the Report on Cleanroom Technology in Healthcare Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/1003 Request Sample of the Report on Cleanroom Technology in Healthcare Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/1003 Prime determinants of growth The global cleanroom technology in healthcare market is experiencing growth due to several key factors. As controlled environments have become crucial in...
PR Newswire
17/11/2023

The European Commission Approves Label Update for TAKHZYRO® (lanadelumab)…

- Offers a New Preventative Treatment Option for young HAE patients with high unmet need - Offers a New Preventative Treatment Option for young HAE patients with high unmet need ZURICH , Nov. 17, 2023 /PRNewswire/ -- Takeda (TSE:4502/NYSE:TAK) today announced the European Commission has approved TAKHZYRO® (lanadelumab) for the routine prevention of recurrent attacks of Hereditary Angioedema (HAE) in patients aged 2 years and older 1, expanding its initial approved use and...
PR Newswire
17/11/2023

Global Health Informatics Market to Garner a Valuation of $101.34 Billion by…

Get a Sample PDF of the Report: https://www.kingsresearch.com/request-sample/health-informatics-market-155 Get a Sample PDF of the Report: https://www.kingsresearch.com/request-sample/health-informatics-market-155 Trending Now: NYU Langone Health promotes generative AI innovation with 'prompt-a-thon'NYU Langone Health is leading the charge in generative AI innovation with its inaugural Generative AI Prompt-A-Thon in Health Care. Clinicians, researchers, and educators came...
PR Newswire
17/11/2023

Uppsala University Hospital and Sana Biotechnology Announce Authorization of the…

Goal is to report UP421 proof of concept data in 2023 and 2024 Potential to remove immunosuppression from islet cell transplantation SEATTLE, Nov.17, 2023(GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, and Uppsala University Hospital in Sweden today announced the Swedish Medical Products Agency has authorized Uppsala University's Clinical Trial Application (CTA) to initiate an...
Nasdaq GlobeNewswire
17/11/2023

Oncoclínicas has Net Profit of R$149 million (162% higher vs 3Q22) and Gross…

"We continued to expand at over 20% a year even without any new acquisitions in the period. 2023 has been a year in which we have keep on delivering all the synergies and value creation initiatives that we said we would deliver over the last two years. All this in line with our thesis and business model that puts the patient at the center of everything", highlights Bruno Ferrari, founder and CEO of Oncoclínicas & Co. "We continued to expand at over 20% a year even without any…
PR Newswire
17/11/2023

Increase Prevalence of Diabetic Patients Driving Market Growth Projected to…

PALM BEACH, Fla., Nov. 17, 2023 /PRNewswire/ -- The global diabetes therapy and treatment market is driven primarily by increased diabetes prevalence, sedentary lifestyles, and most other chronic diseases, such as hypertension. According to the International Diabetes Federation (IDF), approximately 537 million adults (20-79 years) have diabetes, with the number of diabetic patients expected to rise to 643 million by 2030 and 783 million by 2045. As a result, the rising prevalence of diabetes in…
PR Newswire
17/11/2023

Implantica presents the third quarter 2023 on November 22 at 15:00 CET

If you wish to participate via webcast, please use the following link: If you wish to participate via webcast, please use the following link: If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference. Speakers: For further information, please contact: Nicole Pehrsson, Investor Relations Telephone (CH): +41 (0)79 335 09 49nicole.pehrsson@implantica...
PR Newswire
17/11/2023

Seeding Future: Hayashibara's 25th Trehalose Symposium Highlights Breakthroughs…

Under the theme of "Trehalose Leading a Sustainable Future," the symposium featured various research outcomes. These included promising treatments using three-dimensional cultures and dermal sheets from fibroblasts processed with highly concentrated trehalose, the design of stem cell preservation solutions, and the applications in hair care products and livestock feed. The chemistry and biological functions of trehalose-based compounds were also presented. Particularly noteworthy was…
PR Newswire
17/11/2023

Mendus Announces Nomination Committee for the 2024 Annual General Meeting

Press Release Stockholm, Sweden, November 17, 2023Mendus AB (publ: IMMU.ST) announced today that the members of the Nomination Committee have been appointed in accordance with the principles for appointment of the Nomination Committee, adopted by the Annual General Meeting of May 4, 2021. The members of Mendus' Nomination Committee shall be appointed by the four largest shareholders, as of August 31, 2023, who wish to exercise their right to appoint a representative. If four...
Nasdaq GlobeNewswire
17/11/2023

94.1 percent of Kuwaiti Women Consider Thalassemia Screening after Learning…

94.1% of Kuwaiti women consider screening after learning about associated thalassemia health risks and costs which is higher than the global average of 84.5%. If both partners are thalassemia carriers, 38.1% of Kuwaiti women can persuade their partners to seek genetic counseling and consider preimplantation genetic diagnosis (PGD) which is lower than the global average of 50.9%. 94.1% of Kuwaiti women consider screening after learning about associated thalassemia health risks and costs which…
PR Newswire
17/11/2023

World Prematurity Day 2023: Pampers launches new online ordering platform for…

For premature babies, sleep is crucial to support their development, with some needing up to 22 hours a day. This vital sleep allows premature babies to catch up on the development they would have when in the womb[4]. However, this sleep is often interrupted due to much-needed medical interventions, which can happen up to 200 times a day. In fact, research by Pampers has shown that 46%[5] of premature babies had their sleep interrupted by medical lines and equipment. It's therefore important…
PR Newswire
17/11/2023

Unraveling the Shifting Rare Eye Diseases Market Landscape: Analysis of…

DelveInsight has expertise in the rare disease market with an experienced team handling the rare disease domain proficiently. DelveInsight has recently released a series of epidemiology-based market reports on rare eye diseases including Retinoblastoma, Retinitis Pigmentosa, Limbal Stem Cell Deficiency, Leber Hereditary Optic Neuropathy (LHON), and Stargardt Disease. These reports include a comprehensive understanding of current treatment practices, emerging drugs, market share of individual…
PR Newswire
16/11/2023
Altri  Comunicati